Device Week, 29 October 2021 – FDA Fiddles With Breast Implant Rules And Releases Favored Guidances Lists
On this week’s podcast: The US FDA put some teeth to its regulation of breast implants by issuing several new mandates, including a requirement that surgeons warn patients about the risks of the devices prior to surgery. Also this week the agency released its annual A/B lists of priority guidance documents.
You may also be interested in...
The US FDA has designated a September recall by Teleflex of its Arrow-Trerotola Over-The-Wire PTD Kit Percutaneous Thrombolytic Device: 7FR as high-risk class I.
Invacare, Smiths Medical and CellEra were cited for quality systems and Medical Device Reporting violations in the only device-related warning letters released by the agency last month.
Blackrock Neurotech’s MoveAgain technology platform allows patients who have been silenced by ALS, paralysis and other spinal cord injuries the ability to better communicate via text. The device has been granted breakthrough status by the US FDA.